Company intelligence / Profile preview

Innovation Pharmaceuticals Inc.

Wakefield, Massachusetts, United Statesipharminc.com ↗

Ownership: Private
Employees: ~4
Development stage: Phase 3

Overview

Lead drug candidate Brilacidin has completed multiple clinical trials with over 500 patients treated to date. It has received FDA Fast Track designation. The company recently completed a Phase 2 clinical trial of Brilacidin for COVID-19 treatment, though the topline results did not meet expectations. Brilacidin has shown promising antifungal activity in preclinical studies against multiple pathogenic fungi.

Therapeutic areas: GastroenterologyInfectious Diseases
Modalities: Small moleculesDefensin-mimetic
Industry: Biotech

Drug pipeline

6 assets

brilacidin

5 more assets in the full pipeline.

Partnerships

Alfasigma S.p.A.Fox Chase Chemical Diversity Center, Inc.NIH/NIAID

Beyond the preview

Go deeper on Innovation Pharmaceuticals Inc..

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on Innovation Pharmaceuticals Inc..